Does Imipenem Anhydrous Cilastatin And Relebactam Anhydrous Interact with Divalproex Sodium?
CDI records a major classification for Imipenem Anhydrous Cilastatin And Relebactam Anhydrous and Divalproex Sodium. The stored summary is: May decrease divalproex sodium concentrations, increasing risk of breakthrough seizures. Concomitant use should be avoided. The mechanism involves carbapenems may inhibit hydrolysis of valproic acid's glucuronide metabolite back to valproic acid, decreasing serum concentrations. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.
- Severity
- Major
- Imipenem Anhydrous Cilastatin And Relebactam Anhydrous Class
- Renal Dehydropeptidase Inhibitor
- Management
- Close medical supervision required
- Data Source
- U.S. FDA via OpenFDA
Recorded Mechanism
Carbapenems may inhibit hydrolysis of valproic acid's glucuronide metabolite back to valproic acid, decreasing serum concentrations
What To Tell Your Doctor or Pharmacist
If you are taking Imipenem Anhydrous Cilastatin And Relebactam Anhydrous and your doctor is considering prescribing Divalproex Sodium (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask how frequently you should be monitored while these are co-prescribed
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider